Compare GLOO & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLOO | PRLD |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.7M | 260.2M |
| IPO Year | 2025 | 2020 |
| Metric | GLOO | PRLD |
|---|---|---|
| Price | $2.58 | $3.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $11.17 | $8.80 |
| AVG Volume (30 Days) | 232.2K | ★ 257.6K |
| Earning Date | 09-09-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.17 | 23.21 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $94,660,000.00 | $12,140,000.00 |
| Revenue This Year | $111.41 | $74.34 |
| Revenue Next Year | $42.96 | $85.56 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 307.74 | 73.43 |
| 52 Week Low | $2.60 | $1.30 |
| 52 Week High | $9.98 | $6.83 |
| Indicator | GLOO | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 30.49 | 36.56 |
| Support Level | N/A | $2.69 |
| Resistance Level | $3.20 | $3.32 |
| Average True Range (ATR) | 0.23 | 0.31 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 11.42 | 6.32 |
Gloo Holdings Inc is engaged in building a technology platform company. It has provided a breadth of products, services, and solutions to the two primary stakeholders at the core of the faith and flourishing ecosystem: (1) network capability providers (NCPs) and (2) the churches and frontline organizations (CFLs) it serves. The company serves as a digital infrastructure between NCPs and CFLs. By facilitating efficient exchange between the two, Gloo enables both sides to succeed; CFLs gain access to resources and NCPs benefit from efficient distribution and targeted reach. This creates a virtuous cycle, strengthening the platform with each interaction. The Gloo platform includes a suite of technology, marketplace, and service solutions offered directly from Gloo or from Gloo's subsidiaries.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.